Apelin Is a Prototype of Novel Drugs for the Treatment of Acute Myocardial Infarction and Adverse Myocardial Remodeling.
Sergey V PopovLeonid N MaslovAlexander V MukhomedzyanovBoris K KurbatovAlexandr S GorbunovMichail KilinViatcheslav N AzevMaria S KhlestkinaGalina Z SufianovaPublished in: Pharmaceutics (2023)
In-hospital mortality in patients with ST-segment elevation myocardial infarction (STEMI) is 5-6%. Consequently, it is necessary to develop fundamentally novel drugs capable of reducing mortality in patients with acute myocardial infarction. Apelins could be the prototype for such drugs. Chronic administration of apelins mitigates adverse myocardial remodeling in animals with myocardial infarction or pressure overload. The cardioprotective effect of apelins is accompanied by blockage of the MPT pore, GSK-3β, and the activation of PI3-kinase, Akt, ERK1/2, NO-synthase, superoxide dismutase, glutathione peroxidase, matrix metalloproteinase, the epidermal growth factor receptor, Src kinase, the mitoK ATP channel, guanylyl cyclase, phospholipase C, protein kinase C, the Na + /H + exchanger, and the Na + /Ca 2+ exchanger. The cardioprotective effect of apelins is associated with the inhibition of apoptosis and ferroptosis. Apelins stimulate the autophagy of cardiomyocytes. Synthetic apelin analogues are prospective compounds for the development of novel cardioprotective drugs.
Keyphrases
- acute myocardial infarction
- percutaneous coronary intervention
- st segment elevation myocardial infarction
- protein kinase
- epidermal growth factor receptor
- left ventricular
- tyrosine kinase
- signaling pathway
- cell death
- acute coronary syndrome
- st elevation myocardial infarction
- oxidative stress
- advanced non small cell lung cancer
- coronary artery disease
- endoplasmic reticulum stress
- cell proliferation
- pi k akt
- hydrogen peroxide
- cardiovascular disease
- drug induced
- molecular docking
- type diabetes
- nitric oxide
- cardiovascular events
- endothelial cells
- high glucose
- combination therapy